Home Newsfeeds Credit Suisse Maintains Outperform on Prometheus Biosciences, Raises Price Target to $142

Credit Suisse Maintains Outperform on Prometheus Biosciences, Raises Price Target to $142

Credit Suisse analyst Tiago Fauth maintains Prometheus Biosciences (NASDAQ:RXDX) with a Outperform and raises the price target from $59 to $142.

byBenzinga Newsdesk

December 8, 2022

1 minute read

Credit Suisse analyst Tiago Fauth maintains Prometheus Biosciences (NASDAQ:RXDX) with a Outperform and raises the price target from $59 to $142.

Analyst Ratings

Cracking The Code: Understanding Analyst Reviews For BJ’s Wholesale Club

By Benzinga Insights

April 18, 3:02 PM

In the preceding three months, 13 analysts have released ratings for BJ’s Wholesale Club (NYSE:BJ), presenting a wide…

Novavax Updates 2024 Guidance: Expects Combined Revenue And Sanofi Agreement Payments Of $970M-$1.17B (Prior $800M-$1B); And Combined R&D And SG&A Of $700M-$750M (Prior $700M-$800M)

By Benzinga Newsdesk

May 10, 3:23 AM

Financial Framework Novavax is updating its Full Year 2024 Financial Guidance and expects to achieve the following objectives: Full Year 2024 Guidance $ in millions Prior (as

NVAX

BMF-219 Enters the Clinic For KRAS Solid Tumor; Biomea Fusion Announces FDA Clearance Of Investigational New Drug Application For Covalent Menin Inhibitor BMF-219 In KRAS Solid Tumors

By Benzinga Newsdesk

October 14, 9:02 AM

Biomea Fusion announces FDA clearance of Investigational New Drug (IND) application for covalent menin inhibitor BMF-219 in KRAS solid tumors. Biomea Fusion will now initiate a Phase I/Ib clinical trial

BMEA

News

Frontier Airlines And Apijet Announce Agreement To Test Apijet’s Real-Time Route Optimization Technology Furthering Frontier’s Commitment To Fuel Efficiency And Sustainability

By Benzinga Newsdesk

June 13, 9:04 AM

Frontier Airlines (NASDAQ:ULCC), a leader in sustainable aviation and America's Greenest Airline, and APiJET, the technology leader in real-time flight optimization for fuel and carbon savings, today, announced an

ULCC

Credit Suisse Maintains Outperform on Prometheus Biosciences, Raises Price Target to $142

Related Posts

Cracking The Code: Understanding Analyst Reviews For BJ’s Wholesale Club

Novavax Updates 2024 Guidance: Expects Combined Revenue And Sanofi Agreement Payments Of $970M-$1.17B (Prior $800M-$1B); And Combined R&D And SG&A Of $700M-$750M (Prior $700M-$800M)

BMF-219 Enters the Clinic For KRAS Solid Tumor; Biomea Fusion Announces FDA Clearance Of Investigational New Drug Application For Covalent Menin Inhibitor BMF-219 In KRAS Solid Tumors

Frontier Airlines And Apijet Announce Agreement To Test Apijet’s Real-Time Route Optimization Technology Furthering Frontier’s Commitment To Fuel Efficiency And Sustainability